Objectives ICIs have been approved and are routinely administered regardless of
performance status (PS), despite randomized clinical trials of ICIs alone or combined with …

Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …

Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …

Simple Summary The benefit of programmed death-1/programmed death ligand-1 (PD-1/PD-
L1) immunotherapy, particularly of nivolumab, pembrolizumab and atezolizumab, in the …

Background Nivolumab has promising efficacy for the treatment of non‐small cell lung
cancer (NSCLC). Various predictive factors for nivolumab response in those with NSCLC …

Immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1) and PD-ligand 1
(PD-L1) quickly subverted the standard of treatment in Non-Small Cell Lung Cancer …

Introduction Immune-related adverse events (irAEs) constitute a challenge in the clinical
management of solid tumors. This study aims to collect real-world data on the occurrence of …

Background: Cancer-associated thrombosis (CAT) and venous thromboembolism (VTE) are
frequent cancer-related complications associated with high mortality; thus, this urges the …

Background Pembrolizumab is licensed for the treatment of pre-treated and PD-L1 positive
non-small cell lung cancer (NSCLC), but response is heterogeneous. In this context, the …

Background Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the
standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here …